Monitor for closure of the Psyga acquisition and details on the issuance of shares under the private placement. The authorized share increase of 2.9B shares provides significant capacity for future equity raises, which could pressure the stock price if exercised. The $1.5M private placement represents ~25% of current market cap and will be dilutive if completed.
Price Chart
Executive Summary
XTL Biopharmaceuticals held its Extraordinary General Meeting on June 29, 2026, and all proposals were approved. Proposals include the acquisition of 80-100% of Psyga Bio Ltd. via share issuance and milestone warrants, a private placement of up to $1.5M from Alexander Rabinovitch, and an increase in authorized share capital by 2.9 billion shares (to 5.8 billion total). The massive authorized share increase signals potential for significant dilution, though the acquisition could provide new growth avenues for this micro-cap.
Key Facts
- Approved acquisition of 80-100% of Psyga Bio Ltd. in exchange for shares and milestone warrants
- Approved private placement of up to $1,500,000 from Alexander Rabinovitch and/or other investors, conditional on the transaction
- Approved increase of authorized share capital by 2,900,000,000 shares, to a total of 5,800,000,000 ordinary shares
- Approved appointment of Barzily & Co. as independent auditor for fiscal year 2025
Financial Impact
Authorized share capital increased by 2.9 billion shares, from current to 5.8 billion total; private placement of up to $1.5 million
Risk Factors
- Massive dilution from the authorized share increase if shares are issued
- Execution risk in closing the Psyga acquisition
- Potential need for further capital raises given small market cap and cash position (not disclosed)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-073158 |
| Document: 0001213900-26-073158-index-headers.html | 0001213900-26-073158 |
| Document: 0001213900-26-073158-index.html | 0001213900-26-073158 |
| Document: 0001213900-26-073158.txt | 0001213900-26-073158 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 6-K | $1.91 | awaiting T+60 | — | $1.82 (−4.71%) |
Jun 30, 2026 16w ago | 20-F | $2.49 $2.41 | ▲ +3.21% | ▲ +6.08% | $1.82 (+26.91%) |
Jun 29, 2026 17w ago | 6-K | $2.73 $2.20 | ▼ −19.41% | ▼ −22.23% | $1.82 (−33.33%) |
May 22, 2026 22w ago | 6-K | $2.38 $2.98 | ▼ −25.21% | ▼ −22.49% | $1.82 (+23.53%) |
May 7, 2026 24w ago | 6-K | $2.67 $2.86 | ▲ +7.15% | ▲ +3.31% | $1.82 (−31.84%) |
Apr 29, 2026 25w ago | 6-K | $3.56 $2.94 | ▼ −17.42% | ▼ −21.53% | $1.82 (−48.88%) |
Apr 29, 2026 25w ago | Press Release | $3.56 $2.94 | ▼ −17.42% | ▼ −21.53% | $1.82 (−48.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers